Remove FDA Approval Remove Insulin Remove Pharmacy Remove Production
article thumbnail

FDA approves first interchangeable biosimilar insulin product for treatment of diabetes

The Pharma Data

Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. for the treatment of diabetes. Biosimilars marketed in the U.S.

Insulin 52
article thumbnail

Top 15 Diabetes Drugs in 2023 by 2022 Sales Statistics

XTalks

Ozempic (Semaglutide) Ozempic sales in 2022: $8.713 billion Company/Developer: Novo Nordisk Date of first FDA approval: December 5, 2017 Indications Ozempic is FDA-approved for: Type 2 diabetes Price of Ozempic: $1,029 for 1.5 Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics.

Sales 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Warns About Compounded Versions of Ozempic and Wegovy

XTalks

GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness. As of May 2023, both Ozempic and Wegovy were on the FDA’s Drug Shortages list due to a global shortage of semaglutide. mg and 2.4 mg doses of Wegovy.

article thumbnail

The US biosimilar market: Predictions for 2021

pharmaphorum

When Merck launched Ontruzant last April, the trastuzumab market became the most competitive to date with five biosimilars competing against the reference product. Pegfilgrastim and Infliximab follow closely behind with four and three biosimilars respectively competing against the reference product in each market. “We

Marketing 118
article thumbnail

STAT+: Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

STAT News

… Pharmaceutical companies could be made to disclose prices and deals for products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord , Reuters reports. A The first therapy that delays the onset of type 1 diabetes received approval from the U.S.

Insulin 98
article thumbnail

Five things to watch as the Biosimilars market heats up in 2022

pharmaphorum

And already in the first quarter of 2022, the FDA approved a third filgrastim biosimilar, Releuko. With 34 approved biosimilars and dozens more in the pipeline, what does this year have in store? In September of 2021, the FDA approved Byooviz , which references Roche and Novartis’ blockbuster eye drug Lucentis.

article thumbnail

STAT+: Pharmalittle: J&J drops out of bidding for Horizon; FDA takes a harder line on fast-track approvals

STAT News

Meantime, the FDA told ImmunoGen and ADC Therapeutics, which have been developing cancer drugs, that it would not grant a speedy approval until they had begun follow-up studies. Dr Reddy’s Laboratories and Sun Pharma are recalling different products in the U.S. Food and Drug Administration.

Insulin 52